ArticleJournal of the Pediatric Orthopaedic Society of North America2026
Allogeneic Transfusion-related Adverse Events in Pediatric Idiopathic Scoliosis Surgery.
Article in Journal of the Pediatric Orthopaedic Society of North America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pediatric spinal deformity surgery can involve significant perioperative blood loss, and allogeneic blood transfusion has been linked to an increased risk of adverse events. This study aimed to quantify adverse events associated with allogeneic blood transfusion in pediatric idiopathic scoliosis surgery. Study design/setting: Retrospective observational cohort study. Methods: The National Surgical Quality Improvement Program (NSQIP) Pediatric database (2016-2022) was queried. Patients <18 years undergoing posterior arthrodesis with 7 or more surgical levels for idiopathic scoliosis were included. The primary outcome was a composite 30-day adverse event outcome. Chi-square tests were used to compare the rates of adverse events associated with allogeneic blood transfusion. A multivariable logistic regression analysis was performed to assess the association between allogeneic blood transfusion and the occurrence of adverse events. Results: A total of 23,106 patients were included in this study, of which 12.3% received allogeneic transfusion. The rate of the composite 30-day adverse event outcome was 1.1%. Patients that received allogeneic transfusion had a higher rate of 30-day adverse event (2.5% vs 0.9%; X Conclusions: In this large national pediatric registry cohort, allogeneic transfusion was associated with higher odds of 30-day adverse events after posterior spinal fusion for idiopathic scoliosis. Further prospective and center-level studies are needed to clarify transfusion thresholds, blood management strategies, and potential contributors to adverse outcomes. Key Concepts: (1)In 23,106 pediatric idiopathic scoliosis patients from the American College of Surgeons National Surgical Quality Improvement Program, 12.3% received allogeneic transfusion and the overall 30-day composite adverse event rate was 1.1%.(2)Patients who received allogeneic transfusion had a significantly higher rate of composite 30-day adverse events compared to those who did not (2.5% vs 0.9%, Level of Evidence: Level III.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.